Deadline for LEAD Grant Proposals is April 30, 2011
King of Prussia, PA — 06 April 2011
CSL Behring, a global leader in the plasma protein biotherapeutics industry, is accepting grant requests through its Local Empowerment for Advocacy Development (LEAD) program through April 30, 2011. The LEAD program awards funds to United States patient organizations that assist people with rare diseases in advocating for continued access to health care and life-saving plasma protein therapies.
To date, the LEAD program has awarded nearly $600,000 to 34 patient organizations for their use in funding grassroots advocacy initiatives. Those initiatives include developing core advocacy and grassroots capabilities and advocating on issues to improve access to care.
To qualify for a LEAD grant, a patient organization must:
- Be a non-profit with 501(c)(3) tax status;
- Represent people who use plasma protein therapies to treat coagulation disorders, immune deficiencies, hereditary angioedema, genetic emphysema or other conditions reliant on plasma-derived therapies; and
- Demonstrate that financial assistance will help the group or organization advance important local or state advocacy initiatives.
According to Dennis Jackman, CSL Behring’s Senior Vice President, Global Public Affairs, LEAD grants underscore the company’s commitment to saving and improving the lives of people with rare and serious illnesses. “LEAD grants provide greatly needed financial resources to sustain the efforts of patient organizations as they focus on complex legislative and public policy issues,” Jackman says.
Applications, specific criteria for applying and additional information about the LEAD program are available on the CSL Behring Website at www.cslbehring.com/leadgrants.
About CSL Behring
CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide.
CSL Behring therapies are indicated for the treatment of coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease. The company’s products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in newborns.
CSL Behring operates one of the world’s largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of
CSL Limited (ASX: CSL), a biopharmaceutical company headquartered in Melbourne, Australia. For more information, visit
Manager, Corporate Communications